Bank of America
ARQT icon

Bank of America’s Arcutis Biotherapeutics ARQT Stock Holding History

Bank of America’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,000
Closed -$347K – 7730
2021
Q1 		$347K Buy
+12,000
New +$375K ﹤0.01% 5654

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America's ARQT Position: Q1 2026 in Review

Bank of America increased its Arcutis Biotherapeutics (ARQT) stake by 33% in Q1 2026, buying an estimated $14M and bringing the position to 2,221,289 shares worth $52.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1569.

Bank of America first reported a position in ARQT in Q1 2020 and has held it in 25 quarters since. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Bank of America held 2,221,289 shares of Arcutis Biotherapeutics worth $52.3M as of Q1 2026.
  • Bank of America bought 547,835 Arcutis Biotherapeutics shares in Q1 2026, an estimated $14M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1569 holding.
  • Bank of America first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 25 quarters since.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.